Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.
Treatment intensification with the androgen receptor inhibitor enzalutamide shows benefit in patients with biochemically recurrent prostate cancer. Data show enzalutamide treatments are safe and effective compared with ADT alone in patients with high-risk biochemically recurrent prostate cancer.
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer-; both of which helped patients live longer without their disease progressing than the current standard treatment.